Literature DB >> 23994885

Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.

Tetsuzo Tagawa1, Licun Wu, Masaki Anraku, Zhihong Yun, Katrina Rey-McIntyre, Marc de Perrot.   

Abstract

CD1d-restricted natural killer T (iNKT) cells have been shown to provide adjuvant activity against cancer by producing interferon (IFN)-γ. However, the role of invariant NKT (iNKT) cells in the tumor microenvironment has not yet been fully addressed. Our aim is to elucidate the antitumor effect of iNKT cells in the tumor microenvironment by using an intrathoracic murine malignant pleural mesothelioma model that we had previously developed and to provide pleural effusion as a good surrogate of the tumor microenvironment. We found that the number of iNKT cells increased dramatically in the pleural effusion after intrathoracic tumor cell injection at an earlier phase compared with accumulation of CD8 T cells. These iNKT cells showed increased expression of CD25 and increased ratio of cells positive for IFN-γ intracellular staining. iNKT cells sorted from pleural effusion of tumor burden mice produced larger amount of IFN-γ compared with naive mice. Mice pretreated in vivo with anti-CD1d-blocking Ab showed increased amount of pleural effusion and decreased ratio of total and effector-type CD8 T cells as well as decreased intracellular IFN-γ expression of CD8T-cell in the pleural effusion. In vivo administration of α-galactosylceramide (α-GalCer) showed prolonged survival associated with less pleural effusion and increased ratio of IFN-γ-positive iNKT cells and CD8 T cells in the pleural effusion. Therefore, this study suggests that iNKT cells accumulating in the tumor microenvironment play an antitumor effect by producing IFN-γ and enhancing subsequent CD8 T-cell response. Furthermore, in vivo administration of α-GalCer could suppress mesothelioma growth by activating iNKT cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23994885     DOI: 10.1097/CJI.0b013e3182a801f2

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  4 in total

Review 1.  Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.

Authors:  Licun Wu; Marc de Perrot
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma.

Authors:  Iwona Hus; Agnieszka Bojarska-Junak; Marzena Kamińska; Aneta Dobrzyńska-Rutkowska; Karolina Szatan; Agnieszka Szymczyk; Bożena Kukiełka-Budny; Dariusz Szczepanek; Jacek Roliński
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

Review 3.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

4.  Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.

Authors:  Licun Wu; Walter Blum; Chang-Qi Zhu; Zhihong Yun; Laszlo Pecze; Mikihiro Kohno; Mei-Lin Chan; Yidan Zhao; Emanuela Felley-Bosco; Beat Schwaller; Marc de Perrot
Journal:  BMC Cancer       Date:  2018-04-27       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.